Biologics manufacturing is where much of the money and most of the strategic tension in contract manufacturing now sits. Demand from antibodies, ADCs, and the GLP-1 boom has strained capacity, geopolitics is redrawing the supply map, and a handful of players are investing billions to capture what is coming. Here is a clear guide to the leading biologics CDMOs in 2026 and how to think about choosing one.
The capacity race defines the market
The story of biologics manufacturing right now is capacity: who has it, who is building it, and where. Enormous demand has pushed the largest players into a construction race, with billions invested in new plants, particularly in the United States, and industry trackers counting hundreds of CDMO expansion announcements in a single year. At the same time, US policy aimed at certain Chinese providers has prompted many Western sponsors to rethink dependence on Chinese manufacturing, accelerating a shift of capacity toward the US, Europe, South Korea, and India. For sponsors, this means capacity availability and geographic footprint have become first-order selection criteria, not afterthoughts.
The scale leaders
- Samsung Biologics has redefined what large-scale biologics manufacturing looks like, operating what is widely described as the world’s largest biopharmaceutical manufacturing capacity at a single location, with enormous single-use bioreactor capability and a reputation for speed and predictable, consistent commercial supply. Its continued expansion in Incheon has cemented that position.
- Lonza is the other giant, combining deep process science with global capacity, and it strengthened its US position substantially by acquiring a large California biologics plant.
- WuXi Biologics built a formidable position through its integrated platform and has reported a very large order backlog, with particular strength in complex modalities like bispecifics and ADCs, though Western sponsors now weigh policy risk in their planning.
- Thermo Fisher and Fujifilm Diosynth both bring large-scale biologics capability and have been investing heavily, with Fujifilm making a major North Carolina commitment.
The quality and heritage players
Several CDMOs compete less on raw scale than on manufacturing pedigree. Boehringer Ingelheim BioXcellence brings decades of pharma manufacturing heritage to contract work, with a strong reputation in cell culture and microbial fermentation. AGC Biologics and Siegfried serve sponsors needing reliable, quality-focused partners at a range of scales. National Resilience has built out multi-site US capacity with a focus on supply-chain security. And Catalent, now under Novo Holdings, remains a significant force in biologics fill-finish and drug-device combinations. For many sponsors, particularly those in commercial supply where a compliance failure is catastrophic, this pedigree and reliability matter more than being the biggest.
Where ADCs and complex modalities change the calculus
One of the sharpest trends is the scramble for capability in antibody-drug conjugates and other complex formats, which demand specialized capability to combine a biologic, a potent payload, and a linker at pharmaceutical quality. Because ADC pipelines have swelled to hundreds of candidates, conjugation capacity has become a genuine bottleneck, and CDMOs with proven ADC expertise, including Lonza, WuXi, Piramal, and a set of specialists, hold real leverage. Sponsors developing an ADC or a bispecific should treat manufacturing capability as a program-defining constraint and secure a partner far earlier than they would for a conventional antibody.
How to choose
Selecting a biologics CDMO comes down to a handful of decisive factors. Proven experience with your specific modality (a standard antibody is very different from an ADC or a novel format) is the foundation. Genuine available capacity on your timeline is critical in a constrained market, and vague reassurance is a red flag. Quality and regulatory track record is non-negotiable. Technology transfer and scale-up capability determines whether your process actually works at their site. And increasingly, geographic footprint and supply-chain resilience shape the decision, particularly for sponsors with US government exposure or those concerned about concentration risk in a shifting policy environment.
The bottom line
The biologics CDMO market in 2026 is defined by a capacity race and a geopolitical rebalancing, with Samsung Biologics and Lonza anchoring the top tier, WuXi Biologics holding a formidable but policy-exposed position, and players like Thermo Fisher, Fujifilm, Boehringer Ingelheim, and National Resilience competing hard on scale, pedigree, and supply security. The right partner depends on your modality, your scale, your timeline, and how much supply-chain resilience matters to you. Engage early, scrutinize capacity claims, and weight quality and modality-specific experience above all, because in biologics, manufacturing is not a downstream detail but a determinant of whether your program succeeds.
The economics of switching, and why you should not have to
One factor that deserves more weight than it usually gets is the cost of changing biologics manufacturers mid-program, which is high enough that it should shape your original choice. Transferring a biologics process to a new site means repeating substantial process work, re-validating, generating comparability data to demonstrate the product made at the new site is equivalent, and satisfying regulators that nothing material has changed. This is expensive, slow, and carries genuine risk, since comparability problems can delay a program by many months. The implication is that you should choose a partner who can carry you as far as you realistically need to go, ideally from clinical supply through commercial manufacturing, rather than optimizing narrowly for the cheapest or fastest option today and accepting a transfer later. It also means that a CDMO’s ability to scale within its own network, moving you from a development-scale facility to a commercial one under the same quality system, is a genuinely valuable feature worth paying for. When you evaluate partners, ask explicitly about the path from where you are to commercial supply, whether it stays within their network, and what a scale-up would actually involve. A partner who can articulate that path clearly, and has done it before for similar products, is worth considerably more than one offering a marginally better price for the immediate work, because the cost of getting this wrong lands squarely on your timeline at precisely the moment you can least afford it.
A note on this snapshot
Biologics manufacturing is changing faster than almost any part of the industry, with new capacity announced constantly and the policy environment still evolving. Treat the picture here as current context rather than settled fact, verify capacity claims directly, and audit any prospective partner’s quality systems yourself. The reshoring wave in particular means the map of who can make what, where, is being redrawn continuously, so a decision made on last year’s assumptions may already be out of date. Engage early, ask hard questions, and confirm everything, because in a constrained market the difference between a promised slot and an actual one can define your timeline.
Ask about the people, not just the capacity
Capacity numbers and facility tours dominate CDMO evaluations, but your actual experience will be determined by the team assigned to your program: the process development scientists, the tech transfer lead, and the quality people who will handle your product day to day. Insist on meeting them, probe their experience with your specific modality, and judge whether they engage seriously with the technical challenges your process presents. An engaged, experienced team is worth more than an extra bioreactor, and the absence of one is the most common reason capable facilities produce disappointing partnerships.
A word on tech transfer
Whatever partner you choose, treat technology transfer as a project in its own right rather than a handover. It requires your process knowledge to move into their hands completely and accurately, which means good documentation, engaged scientists on both sides, and realistic time. Transfers that are rushed or under-resourced produce the batch failures and comparability problems that derail programs, and they are almost always avoidable. Plan the transfer with the same seriousness you planned the trial it will supply, because a manufacturing setback at the wrong moment costs more than almost any other failure in drug development.
For the full, maintained list of biologics manufacturers, filterable by capability, browse the BioMed Nexus CDMO directory. For related reading, see our guides on choosing a CDMO and our look at the ADC boom that is straining conjugation capacity.
Frequently asked questions
Who are the top biologics CDMOs in 2026?
Samsung Biologics and Lonza anchor the top tier, with Samsung operating what is widely described as the world's largest biopharmaceutical capacity at a single site. WuXi Biologics holds a formidable position with a large backlog and strength in ADCs and bispecifics. Thermo Fisher, Fujifilm Diosynth, Boehringer Ingelheim BioXcellence, AGC Biologics, and National Resilience are other major players.
Why is biologics manufacturing capacity so tight?
Enormous demand from antibodies, ADCs and the GLP-1 boom has strained capacity, pushing the largest players into a construction race with billions invested in new plants. At the same time, US policy aimed at certain Chinese providers has prompted many Western sponsors to shift capacity toward the US, Europe, South Korea and India, further tightening availability.
How do I choose a biologics CDMO?
Prioritize proven experience with your specific modality, since a standard antibody differs greatly from an ADC or novel format; confirm genuine available capacity on your timeline rather than accepting vague reassurance; scrutinize the quality and regulatory track record; assess technology transfer and scale-up capability; and weigh geographic footprint and supply-chain resilience, which have become strategic considerations.
